Efficacy

Efficacy of Ponvory (ponesimod) in Multiple Sclerosis

Ponvory (ponesimod) is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ponesimod works by selectively modulating the S1P1 receptor, which is involved in the movement of lymphocytes in the body. This action helps reduce the migration of damaging lymphocytes to the central nervous system (CNS), thereby decreasing inflammation and neuronal damage.

Clinical trials have demonstrated the efficacy of Ponvory in reducing the annual relapse rate in patients with relapsing forms of MS. In a pivotal phase 3 trial, ponesimod significantly reduced the annual relapse rate compared to another MS drug, teriflunomide, which is a commonly used first-line treatment for MS. Furthermore, Ponvory showed a reduction in the number of new or enlarging T2 lesions and gadolinium-enhancing lesions on MRI scans, which are markers of disease activity in MS.

Efficacy of Briumvi (ublituximab-xiiy) in Multiple Sclerosis

Briumvi (ublituximab-xiiy) is a monoclonal antibody that is currently under investigation for the treatment of relapsing forms of multiple sclerosis. Ublituximab targets a specific protein called CD20 found on the surface of B cells, a type of immune cell implicated in the pathogenesis of MS. By binding to CD20, ublituximab leads to the depletion of B cells, which is thought to reduce the autoimmune attack on the CNS that characterizes MS.

While Briumvi is not yet approved by the FDA for the treatment of MS, clinical trial data has shown promising results. In phase 2 and phase 3 clinical trials, ublituximab has demonstrated a substantial reduction in annual relapse rates for patients with relapsing MS. Additionally, MRI findings have indicated that treatment with ublituximab leads to a significant decrease in new or enlarging T2 lesions and a reduction in the number of T1 gadolinium-enhancing lesions. These findings suggest that Briumvi could be an effective treatment option for patients with relapsing forms of MS, pending FDA approval and further clinical validation.